NASDAQ:TRIB - Trinity Biotech Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.86 -0.05 (-1.28 %)
(As of 08/21/2018 09:51 AM ET)
Previous Close$3.91
Today's Range$3.86 - $3.93
52-Week Range$3.82 - $6.54
Volume2,923 shs
Average Volume47,119 shs
Market Capitalization$84.55 million
P/E Ratio25.25
Dividend YieldN/A
Trinity Biotech logoTrinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research industries. The company sells its products through its direct sales force in the United States; and a network of independent distributors and strategic partners internationally. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.

Receive TRIB News and Ratings via Email

Sign-up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Diagnostic substances


Debt-to-Equity Ratio1.43
Current Ratio5.23
Quick Ratio3.55


Trailing P/E Ratio25.25
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$99.14 million
Price / Sales0.81
Cash Flow$0.2976 per share
Price / Cash12.97
Book Value$2.71 per share
Price / Book1.42


EPS (Most Recent Fiscal Year)N/A
Net Income$-40,270,000.00
Net Margins-41.88%
Return on Equity3.59%
Return on Assets1.32%


Outstanding Shares20,930,000
Market Cap$84.55 million

Trinity Biotech (NASDAQ:TRIB) Frequently Asked Questions

What is Trinity Biotech's stock symbol?

Trinity Biotech trades on the NASDAQ under the ticker symbol "TRIB."

How were Trinity Biotech's earnings last quarter?

Trinity Biotech plc (NASDAQ:TRIB) announced its quarterly earnings data on Thursday, July, 19th. The company reported $0.03 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.06 by $0.03. The company earned $25 million during the quarter. Trinity Biotech had a negative net margin of 41.88% and a positive return on equity of 3.59%. View Trinity Biotech's Earnings History.

When is Trinity Biotech's next earnings date?

Trinity Biotech is scheduled to release their next quarterly earnings announcement on Thursday, October, 25th 2018. View Earnings Estimates for Trinity Biotech.

Who are some of Trinity Biotech's key competitors?

Who are Trinity Biotech's key executives?

Trinity Biotech's management team includes the folowing people:
  • Mr. Ronan O'Caoimh, Co-Founder, Chairman and Chief Exec. Officer (Age 62)
  • Mr. Kevin Tansley, CFO, Sec. & Director (Age 47)
  • Dr. James Walsh Ph.D., Bus. Devel. Director and Exec. Director (Age 60)

Has Trinity Biotech been receiving favorable news coverage?

Media headlines about TRIB stock have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Trinity Biotech earned a daily sentiment score of 0.15 on Accern's scale. They also assigned media stories about the company an impact score of 45.06 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for Trinity Biotech.

Who are Trinity Biotech's major shareholders?

Trinity Biotech's stock is owned by a number of of institutional and retail investors. Top institutional investors include Russell Investments Group Ltd. (6.90%), Lapides Asset Management LLC (5.90%), First Wilshire Securities Management Inc. (4.93%), 22NW LP (4.56%), Heartland Advisors Inc. (4.13%) and Boston Partners (3.99%).

Which institutional investors are selling Trinity Biotech stock?

TRIB stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Heartland Advisors Inc., Millennium Management LLC, Teton Advisors Inc. and Boston Partners.

Which institutional investors are buying Trinity Biotech stock?

TRIB stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, First Wilshire Securities Management Inc., Hunter Associates Investment Management LLC, Lapides Asset Management LLC and 22NW LP.

How do I buy shares of Trinity Biotech?

Shares of TRIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Trinity Biotech's stock price today?

One share of TRIB stock can currently be purchased for approximately $3.86.

How big of a company is Trinity Biotech?

Trinity Biotech has a market capitalization of $84.55 million and generates $99.14 million in revenue each year. Trinity Biotech employs 582 workers across the globe.

How can I contact Trinity Biotech?

Trinity Biotech's mailing address is IDA BUSINESS PARK BRAY, WICKLOW L2, . The company can be reached via phone at 353-1276-9800 or via email at [email protected]

MarketBeat Community Rating for Trinity Biotech (NASDAQ TRIB)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  170 (Vote Underperform)
Total Votes:  294
MarketBeat's community ratings are surveys of what our community members think about Trinity Biotech and other stocks. Vote "Outperform" if you believe TRIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel